natgillin/translations-raw huggingface dataset:
The process according to previous Claims, characterised by the fact that pulsed DC voltage is applied up to 10 KV and at a frequency of up to 250 KHz for the generation of plasma from atmospheric air at a pressure from 8x10-2 to 1x100 mbar in order to begin and conclude the sterilization under vacuum and elimination of the residues. The process according to previous Claims, characterised in that: 
Postupak u skladu s prethodnim patentnim zahtjevima, naznačen time, da se za generiranje plazme iz atmosferskog zraka koristi puls istosmjerne struje napona do 10 KV i frekvencije do 250 KHz, pri tlaku u rasponu od 8×10-2 do 1×10° mbar za početak i završetak sterilizacije pod vakuumom i uklanjanje ostataka.
the resultant evaporation is conducted to the chamber (17) via a needle (15); 
tako dobivena para se provodi u komoru (17) kroz iglu (15);
the remnant of the solution (ML) present in the ampoule (18) is evaporated under vacuum with heating; 
ostatak otopine (ML) koji se nalazi u ampuli (18) isparava se pod vakuumom uz zagrijavanje;
the sterilizing vapour is conducted to the chamber (17) via the needle (15); 
para za sterilizaciju dovodi se u komoru (17) kroz iglu (15);
the sterilizing vapour present in the chamber (17) is conducted to the chamber (1) via the valve (9), where it is expanded and diffused on the articles (M) which are to be sterilized. 
para za sterilizaciju koja se nalazi u komori (17) dovodi se u komoru (1) preko ventila (9), u kojoj se širi i rasprostire po predmetima (M) koje treba sterilizirati .
in the application by application means of vapour of a solution of hydrogen peroxide and residual gas plasma from atmospheric air, excited by pulsed electrical discharge; 
se namjenskim sklopom primjenjuje para iz otopine vodikovog peroksida i rezidualna plinska plazma iz atmosferskog zraka, pobuđena pulsnim električnim pražnjenjem;
in that the vacuum system further comprises at least one liquid ring pump (5), connected in parallel and linked to said chamber (1) by valves (6) and (7); 
vakuumski sustav dodatno sadrži najmanje jednu crpku s tekućim prstenom (5), spojenom paralelno i povezanom s navedenom komorom (1) pomoću ventila (6) i (7);
in that the interior of the chamber (1) is provided with a stand (12), composed of flat surfaces, which, as well as serving to give support to the articles (M) which are to be sterilized, also comprise electrodes (E) at which the plasma is formed for the sterilization process; 
se u unutrašnjosti komore (1) nalazi stalak (12), koji čine ravne površine, koje, osim što služe kao nosači za predmete (M) koje treba sterilizirati, također uključuju i elektrode (E) na kojima nastaje plazma koja se koristi u postupku sterilizacije;
in that the programmable logic controller (14) is responsible for: 
namjena programabilnog logičkog kontrolera (14) je:
A compound according to claim 1 which is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je to spoj odabran iz skupine koja se sastoji od sljedećih spojeva:
and pharmaceutically-acceptable salts and solvates thereof. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to anyone of claims 1 to 11 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time, da sadrži terapijski učinkovitu količinu spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 11 i farmaceutski prihvatljiv nosač.
The pharmaceutical composition of claim 12, wherein the composition further comprises a therapeutically effective amount of one or more other therapeutic agents, wherein the other therapeutic agent is preferably a corticosteroid, an antichlolinergic agent, or a PDE4 inhibitor. 
Farmaceutski pripravak iz patentnog zahtjeva 12, naznačen time, da taj pripravak dodatno sadrži terapijski učinkovitu količinu jednog ili više drugih terapijskih sredstava, pri čemu je drugo terapijsko sredstvo poželjno kortikosteroid, antikolinergijsko sredstvo ili inhibitor PDE4.
The compound or pharmaceutical composition of claim 14 wherein the disease or condition is (a) a pulmonary disease, preferably asthma or chronic obstructive pulmonary disease, or (b) a disease or condition selected from the group consisting of pre-term labor, glaucoma, neurological disorders, cardiac disorders, and inflammation. 
Spoj ili farmaceutski pripravak iz patentnog zahtjeva 14, naznačen time, da je dotična bolest ili stanje (a) plućna bolest, poželjno je astma ili kronična opstruktivna plućna bolest ili (b) bolest ili stanje odabrana iz skupine koja obuhvaća: preuranjene trudove, glaukom, neurološke poremećaje, srčane poremećaje i upale.
Providing a set of expression vectors, wherein each of said vectors comprises at least one copy of a distinct nucleic acid encoding a distinct member of said polyclonal protein; 
Osiguravanju skupa ekspresijskih vektora, gdje svaki od navedenih vektora sadrži najmanje jednu kopiju različite nukleinske kiseline koja kodira poseban član navedenog poliklonskog proteina;
Mixing said 2 to n compositions of cells to obtain a polyclonal cell line. 
Miješanju navedenih 2 do n kompleksa stanica kako bi se dobilo poliklonsku staničnu liniju.
The method of claim 1 or 2, wherein the transfected cells obtained in step b) are cloned, e.g. using FACS cloning, and preferably wherein clones are selected for at least one criterion selected from the group consisting of growth rate, doubling time, expression level, production level, stability of production over time, viability, hardiness, robustness, morphology and copy number. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što transficirane stanice, dobivene u koraku b), se klonira, primjerice putem FACS kloniranja, a po mogućnosti kada se klonove bira za najmanje jedan kriterij, kojeg se bira iz skupine koju čine brzina rasta, vrijeme udvostručavanja, razina ekspresije, razina proizvodnje, stabilnost proizvodnje u vremenu, vijabilnost, izdržljivost, robustnost, morfologija i broj kopija.
The method of any of the preceding claims, wherein the polyclonal protein is a multimeric protein, e.g. wherein one expression vector encodes all subunits of one distinct polyclonal protein member, or wherein the set of expression vectors in step a) is constituted by two or more subsets of expression vectors, where a first subset comprises variant nucleic acid sequences encoding one subunit of the protein, e.g. an antibody heavy chain, and a second subset comprises variant nucleic acid sequences encoding another subunit of the protein, e.g. an antibody light chain, such that each transfection is performed with a member from the first subset and a member from the second subset of expression vectors. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što poliklonski protein je multimerni protein, primjerice kada jedan ekspresijski vektor kodira sve podjedinice jednog posebnog člana poliklonskog proteina, ili gdje skup ekspresijskih vektora u koraku a) čine dva ili više podskupova ekspresijskih vektora, gdje prvi podskup čine varijante sljedova nukleinskih kiselina koji kodiraju jednu podjedinicu proteina, primjerice teški lanac protutijela, a drugi podskup čine varijante sljedova nukleinskih kiselina koji kodiraju drugu podjedinicu proteina, primjerice laki lanac protutijela, tako da se svako transficiranje provodi članom prvog podskupa i članom drugog podskupa ekspresijskih vektora.
The method of any of the preceding claims, wherein the expression vector or a further expression vector encodes a selectable marker, e.g. wherein cells are continuously cultured under conditions favouring growth of cells expressing the selectable marker, e.g. wherein the selectable marker is a gene product in which the host cell is deficient, for example wherein the selectable marker is encoded by a transcript that also encodes a polypeptide member or a subunit of said polypeptide member, preferably wherein the selectable marker is encoded by the transcript encoding the largest subunit. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ekspresijski vektor ili daljnji ekspresijski vektor kodira selektibilni marker, primjerice kada se stanice kontinuirano uzgaja u uvjetima koji favoriziraju rast stanica koje eksprimiraju selektibilni marker, primjerice kada je selektibilni marker genski produkt koji nedostaje staniC1-domaćinu, primjerice kada je selektibilni marker kodiran od strane transkripta koji također kodira polipeptidni član ili podjedinicu navedenog polipeptidnog člana, po mogućnosti kada je selektibilni marker kodiran od strane transkripta koji kodira najveću podjedinicu.
The method of any of the preceding claims, wherein the host cells are eukaryotic cells, preferably mammalian cells, e.g. mammalian cells selected from the group consisting of Chinese hamster ovary (CHO) cells, COS cells, BHK cells, myeloma cells (e.g., Sp2/0 cells, NSO, YB2/0), NIH 3T3 cells, fibroblast or immortalised human cells such as HeLa cells, HEK293 cells, or PER. C6 cells. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što stanice-domaćini su eukariotske stanice, po mogućnosti stanice sisavaca, primjerice stanice sisavca koje se bira iz skupine koju čine stanice jajnika kineskog hrčka (CHO), stanice COS, stanice BHK, stanice mijeloma (primjerice Sp2/0 stanice, NSO, YB2/0), stanice NIH 3T3, fibroblasti ili imortalizirane ljudske stanice, poput stanica HeLa, stanice HEK293 ili stanica PER.
culturing the polyclonal cell line under conditions allowing for expression of the polyclonal protein; 
uzgajanju poliklonske stanične linija u uvjetima koji omogućuju ekspresiju poliklonskog proteina;
The polyclonal cell line of any of claims 14-18, wherein the expression constructs encode a selectable marker, optionally wherein the selectable marker is encoded by a transcript that also encodes a polypeptide member or a subunit of said polypeptide member. 
Poliklonska stanična linija skladu s bilo kojim od patentnih zahtjeva 14-18, naznačena time što ekspresijski konstrukti kodiraju selektibilni marker, izborno kada je selektibilni marker kodiran od strane transkripta koji također kodira polipeptidni član ili podjedinicu navedenog polipeptidnog člana.
The polyclonal cell line of any of claims 14-21, wherein the cells comprise a stably integrated expression construct coding for a transactivator capable of transactivating the promoter coding for the members of the polyclonal protein. 
Poliklonska stanična linija skladu s bilo kojim od patentnih zahtjeva 14-21, naznačena time što stanice sadrže stabilno integrirani ekspresijski konstrukt koji kodira transaktivator koji može transaktivirati promotor koji kodira članove poliklonskog proteina.
Formulation in accordance with any of the previous claims, wherein the fatty/lipophilic component is selected from the group formed by paraffin, vaseline, mineral oil, vegetable oils and hydrogenated vegetable oils. 
Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što masnu odnosno lipofilnu komponentu se bira iz skupine koju čine parafin, vazelin, mineralno ulje, biljna ulja i hidrogenirana biljna ulja.
1- dissolving the preservatives in distilled water, adding, if necessary, an acidifying agent until obtaining a pH between 2.5 and 3.5, so the polymers do not gel in the following step, 
otapanja konzervansa u destiliranoj vodi, te dodavanja, po potrebi, sredstva za zakiseljavanje dok se ne postigne pH između 2,5 i 3,5, tako da se polimeri ne želiraju u sljedećem koraku,
3- adding the neutralizing agent to the mixture of the previous step, stirring it until attaining a pH between 4 and 5, suitable for polymer gelling and for vaginal application, 
dodavanja sredstva za neutraliziranje u smjesu iz prethodnog koraka, uz miješanje, dok se ne postigne pH između 4 i 5, pogodan za želiranje polimera i primjenu u vaginu,
Process in accordance with claim 11, characterized in that it further comprises dissolving or dispersing estriol in the hydrating/wetting agent before incorporating it in the gel. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se dodatno sastoji u otapanju ili dispergiranju estriola u sredstvu za hidrataciju odnosno vlaženje prije dodavanja u gel.
Process for the preparation of the formulations in accordance with claims 1 to 10 characterized in that it comprises the steps of: 
Postupak priprave formulacija u skladu s patentnim zahtjevima 1 do 10, naznačen time što se sastoji u koracima:
1' dissolving the preservatives in distilled water, adding an acidifying agent until obtaining a pH between 2.5 and 3.5, so the polymers do not gel in the following step, 
' otapanja konzervansa u destiliranoj vodi, te dodavanja sredstva za zakiseljavanje dok se ne postigne pH između 2,5 i 3,5, tako da se polimeri ne želiraju u sljedećem koraku,
2' adding the gelling polymers to the solution of the previous step, vigorously stirring until achieving perfect dispersion, 
' dodavanja želirajućih polimera u otopinu iz prethodnog koraka, uz snažno miješanje, dok se ne postigne savršena disperzija,
5' adding the neutralizing agent until achieving a pH between 4 and 5, suitable for polymer gelling and vaginal application. 
' dodavanja sredstva za neutraliziranje dok se ne postigne pH između 4 i 5, pogodan za želiranje polimera i primjena u vaginu.
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS 
LIJECENJE AMIOTROFNE LATERALNE SKLEROZE
-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE 
DERIVAT 2-AMINOBICIKLO[3.1.0]HEKSAN-2,6-DIKARBOKSILNOG ESTERA
QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS 
DERIVATI KINUKLIDINA I NJIHOVA UPORABA KAO ANTAGONISTA MUSKARINSKIH M3 RECEPTORA
ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS 
DERIVATI ADENOZINA KAO AGONISTI A2A RECEPTORA
PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS 
DERIVATI PIRIDAZINONA KAO AGONISTI RECEPTORA TIROIDNIH HORMONA
PYRIDO-PYRAZINE DERIVATIVES USEFUL AS HERBICIDAL COMPOUNDS 
DERIVATI PIRIDO-PIRAZINA KORISNI KAO HERBICIDNI SPOJEVI
PLASTERBOARD PANEL FOR ACCESS TO A COMPARTMENT 
GIPS KARTONSKA PLOCA ZA PRISTUP PRETINCU
PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS 
DERIVATI PIRAZOLA KAO MODULATORI PROTEIN KINAZE
TOPICAL ANTIBIOTIC COMPOSITION FOR THE PREVENTION OF LYME DISEASE 
TOPIKALNI ANTIBIOTICKI SASTAV ZA PREVENCIJU LAJMSKE BOLESTI
HCV NS5B INHIBITORS 
HCV NS5B INHIBITORI
IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS 
IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2
Pyrazole-amine compounds useful as kinase inhibitors 
ARIL-SUPSTITUIRANI PIRAZOL-AMID SPOJEVI KORISNI KAO INHIBITORI KINAZE
VACCINE PEPTIDE COMBINATIONS AGAINST CAT ALLERGY 
CIJEPIVO KOMBINACIJE PEPTIDA PROTIV ALERGIJE NA MACKE
IMIDAZO- AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I 
IMIDAZO- I TRIAZOLOPIRIDINI KAO INHIBITORI 11-BETA HIDROKSISTEROID DEHIDROGENAZE TIP I
PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES 
POSTUPAK PROIZVODNJE EZETIMIBA I MEĐUPRODUKTI KORIŠTENI U TOM POSTUPKU
SYNTHESIS OF ACYLAMINOALKENYLENE AMIDES USEFUL AS SUBSTANCE P ANTAGONISTS 
SINTEZA ACILAMINOALKENILEN AMIDA KORISNIH KAO ANTAGONISTA SUPSTANCE P
HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES 
SPOJEVI HETEROARILA KORISNI KAO INHIBITORI E1 AKTIVIRAJUĆIH ENZIMA
-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS 
-SUPSTITUIRANI-2-FENILAMINOBENZAMIDI KAO INHIBITORI MEK
METHOD OF TREATING TYPE-2 DIABETES 
METODA LIJEČENJA DIJABETESA TIPA-2
Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual 
POSTUPCI UPORABE RECEPTORA GPR119 ZA IDENTIFIKACIJU SPOJEVA KORISNIH ZA POVEĆANJE KOŠTANE MASE JEDNE OSOBE
DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES 
SMANJIVANJE POTENCIJALNIH JATROGENSKIH RIZIKA POVEZANIH S CJEPIVIMA PROTIV GRIPE
BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX 
DERIVATI BENZIMIDAZOLA I NJIHOVA UPORABA ZA MODULACIJU GABAA RECEPTORSKOG KOMPLEKSA
AGENT FOR USE IN THE CASE OF INTESTINAL FRUCTOSE INTOLERANCE 
GLUKOZA IZOMERAZE ZA UPORABU U LIJEČENJU INTOLERANCIJE FRUKTOZE
Coated paper for offset printing 
PAPIR S PREMAZOM ZA OFFSET TISAK
OPTIMIZED DNA AND PROTEIN SEQUENCE OF AN ANTIBODY TO IMPROVE QUALITY AND YIELD OF BACTERIALLY EXPRESSED ANTIBODY FUSION PROTEINS 
OPTIMIZIRANI DNA I PROTEINSKI SLIJED ZA PROTUTIJELO RADI POBOLJŠAVANJA KVALITETE I PRINOSA PROTUTIJELNIH FUZIJSKIH PROTEINA EKSPRIMIRANIH OD STRANE BAKTERIJA
IMPROVEMENT OF A DRY POWDER INHALER 
POBOLJŠANJE INHALATORA ZA SUHI PRAŠAK
Mutant AOX1 promoters 
PROMOTORI MUTANTNE AOX1
CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE 
KRISTALNA BAZA ESCITALOPRAMA I ORODISPERZIBILNE TABLETE KOJE SADRŽE BAZU ESCITALOPRAMA
Decreasing potential iatrogenic risks associated with vaccine antigens 
SMANJIVANJE POTENCIJALNIH JATROGENSKIH RIZIKA POVEZANIH S CJEPIVIMA PROTIV GRIPE
TRAP FOR CATCHING WOODLAND, GARDEN AND AGRICULTURAL INSECT PESTS AND METHOD FOR TRAPPING AND STORING WOODLAND, GARDEN AND AGRICULTURAL INSECT PESTS 
ZAMKA ZA HVATANJE ŠUMSKIH, VRTNIH I POLJOPRIVREDNIH KUKACA NAMETNIKA I POSTUPAK ZA HVATANJE I DRŽANJE ŠUMSKIH, VRTNIH I POLJOPRIVREDNIH KUKACA NAMETNIKA
New hybrid system for brassica napus 
NOVI HIBRIDNI SUSTAV ZA ULJENU REPICU (BRASSICA NAPUS)
Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic 
ORALNI FARMACEUTSKI OBLICI DOZIRANJA OTPORNI NA MANIPULIRANJE KOJI SADRŽE OPIODNI ANALGETIK
POROUS COMPOSITE MATERIAL, PREPARATION PROCESS THEREOF AND USE TO REALIZE TISSUE ENGINEERING DEVICES 
POROZNI KOMPOZITNI MATERIJAL, POSTUPAK NJEGOVE PRIPREME I UPORABA ZA REALIZACIJU UREĐAJA ZA TKIVNI INŽENJERING
Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic 
ORALNI FARMACEUTSKI OBLICI DOZIRANJA OTPORNI NA MANIPULIRANJE KOJI SADRŽE OPIOIDNI ANALGETIK
ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME 
DERIVATI ALFA-AMINOAMIDA KORISNI U TRETMANU POREMEĆAJA UZROKOVANIH OVISNOŠĆU
INVERT MECHANISM FOR A GLASSWARE FORMING MACHINE 
MEHANIZAM ZA OKRETANJE NA STROJU ZA OBLIKOVANJE STAKLENIH PROIZVODA
TYRE CARCASS FORMING METHOD AND DRUM 
POSTUPAK I BUBANJ ZA OBLIKOVANJE KARKASE GUMA
A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION 
NOVI ALFA-(N-SULFONAMIDO)ACETAMIDNI SPOJ KAO INHIBITOR PROIZVODNJE BETA AMILOID PEPTIDA
KINASE INHIBITORS 
INHIBITORI KINAZE
TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE 
S TUMOROM POVEZANI PEPTIDI KOJI SE VEŽU NA MOLEKULE LJUDSKOG LEUKOCITA ANTIGENA (HLA) KLASE I ILI II I SRODNO CJEPIVO PROTIV RAKA
HCV NUCLEOSIDE INHIBITOR 
INHIBITOR HCV NUKLEOZIDA
Composition for transmucosal delivery of polypeptides 
PRIPRAVAK ZA TRANSMUKOZNI UNOS POLIPEPTIDA
METHODS FOR THE PREPARATION OF HEXAHYDROFURO[2,3-B]FURAN-3-OL 
POSTUPCI ZA DOBIVANJE HEKSAHIDROFURO[2,3-B]FURAN-3-OLA
MACHINE FOR CLEANING, WASHING, DRYING AND IRONING CLOTHES AND GARMENTS 
UREĐAJ ZA ČIŠĆENJE, PRANJE, SUŠENJE I GLAČANJE ODJEĆE I ODJEVNIH PREDMETA
VEGETABLE FAT BLEND AND EDIBLE PRODUCTS CONTAINING SUCH A FAT BLEND 
SMJESA BILJNIH MASTI I PREHRAMBENI PROIZVODI KOJI SADRŽE TAKVU SMJESU MASTI
Binding molecules capable of neutralizing rabies virus and uses thereof 
MOLEKULE ZA VEZANJE KOJE MOGU NEUTRALIZIRATI VIRUS BJESNOĆE I NJIHOVA UPORABA
MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS 
MAKROCIKLIČKI INHIBITORI VIRUSA HEPATITISA C
DIHYDROPYRIDINE DERIVATIVES 
DERIVATI DIHIDROPIRIDINA
SUBSTITUTED BICYCLOLACTAM COMPOUNDS 
SUPSTITUIRANI BICIKLOLAKTAMSKI SPOJEVI
MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER 
DERIVATI MALEIMIDA, FARMACEUTSKI PRIPRAVCI I POSTUPCI LIJECENJA RAKA
CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES 
CIKLOALKILAMINSKI SUPSTITUIRANI IZOKINOLINSKI I IZOKINOLINONSKI DERIVATI
Improved sgp 130Fc dimers 
POBOLJSANI sgp 130Fc DIMERI
HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS 
HETEROCIKLICKI-SUPSTITUIRANI PIPERIDINI KAO ORL-1 LIGANDI
PROCESS FOR PREPARING A FILLER FOR ASPHALT OR CONCRETE STARTING FROM A SLAG MATERIAL 
POSTUPAK PRIPREME PUNILA ZA ASFALT ILI BETON POCEVSI OD TROSKE
HIV INHIBITING 5-(HYDROXYMETHYLENE AND AMINOMETHYLENE) SUBSTITUTED PYRIMIDINES 
HIV INHIBIRAJUCI 5-(HIDROKSIMETILEN I AMINOMETILEN) SUPSTITUIRANI PIRIMIDINI
Xanthine derivatives as selective HM74A agonists 
DERIVATI KSANTINA KAO SELEKTIVNI AGONISTI HM74A
Plant for transporting cargo to and/or from a ship 
POSTROJENJE ZA TRANSPORT TERETA NA BROD I/ILI IZ BRODA
Procedure for manufacturing a mattress cover with a padded outer layer and a gusset, and a mattress cover thus manufactured 
POSTUPAK PROIZVODNJE PRESVLAKE MADRACA S PODSTAVLJENIM VANJSKIM SLOJEM I UŠITKOM, TE PRESVLAKA MADRACA PROIZVEDENA NA TAJ NAČIN
PLANT FOR TRANSPORTING CARGO AND/OR FROM A SHIP 
POSTROJENJE ZA TRANSPORT TERETA NA BROD I/ILI IZ BRODA
Decreasing potential latrogenic risks associated with influenza vaccines 
SMANJIVANJE POTENCIJALNIH JATROGENSKIH RIZIKA POVEZANIH S CJEPIVIMA PROTIV GRIPE
TRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES 
TRIAZOLI KORISNI KAO INHIBITORI PROTEIN KINAZA
A device for supporting counter-rotating elements 
UREĐAJ ZA PODRŽAVANJE SUPROTNO-ROTIRAJUĆIH ELEMENATA
MEMANTINE FOR THE TREATMENT OF MILD-TO-MODERATE ALZHEIMER'S DISEASE 
MEMANTIN ZA LIJEČENJE BLAGE-DO-UMJERENE ALZHEIMER-OVE BOLESTI
Triazolone derivative 
DERIVAT TRIAZOLONA
HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 
DERIVATI HETEROARILUREE KORISNI KAO INHIBITORI CHK1
PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES 
FOSFONATI, MONOFOSFONAMIDATI, BISFOSFONAMIDATI ZA LIJEČENJE VIRUSNIH BOLESTI
Antimicrobial composition 
ANTIMIKROBNI SASTAV
Package for mineral wool products, modules to form such package and process to manufacture such a package 
PAKETI ZA PROIZVODE OD MINERALNE VUNE, MODULI ZA OBLIKOVANJE TAKVIH PAKETA I POSTUPAK ZA PROIZVODNJU TAKVOG PAKETA
PURINE DERIVATIVES AS IMMUNOMODULATORS 
DERIVATI PURINA KAO IMUNOMODULATORI
PHARMACEUTICAL COMPOSITIONS CONTAINING ROSUVASTATIN CALCIUM 
FARMACEUTSKI SASTAVI KOJI SADRŽE ROSUVASTATIN-KALCIJ
Prefabricated door or window frame unit with an insulating surround 
MONTAŽNI OKVIRNI ELEMENT ZA VRATA ILI PROZOR S IZOLACIJSKIM OKRUŽENJEM
CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT 
KIMERNI ADENOVIRUSI ZA UPORABU U LIJEČENJU RAKA
METHOD FOR SATURATING CAVITIES PRESENT IN A MASS OF SOIL OR IN A BODY IN GENERAL 
POSTUPAK SATURIRANJA SUPLJINA PRISUTNIH U GOMILI ZEMLJE ILI U NEKOM TIJELU OPCENITO
ORAL COMPOSITIONS FOR ABSORPTION OF PHOSPHORUS COMPOUNDS 
ORALNE SMJESE ZA APSORPCIJU FOSFORNIH SPOJEVA
Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors 
ARIL-SUPSTITUIRANI PIRAZOL-AMID SPOJEVI KORISNI KAO INHIBITORI KINAZE
Peptides for desensibilization against allergens 
PEPTIDI ZA DESENZIBILIZACIJU PROTIV ALERGENA
Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors 
DERIVATI HINAHOLINA KORISNI ZA TRETMAN PERIFERNE ARTERIJSKE BOLESTI I KAO INHIBITORI FOSFODIESTERAZE
CARBAZOLE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS 
DERIVATI KARBAZOLA KAO FUNKCIONALNI LIGANDI 5-HT6
GLUCOSE ISOMERASE FOR USE IN THE TREATMENT OF FRUCTOSE INTOLERANCE 
GLUKOZA IZOMERAZE ZA UPORABU U LIJEČENJU INTOLERANCIJE FRUKTOZE
PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS 
POSTUPAK PROIZVODNJE EZETIMIBA I MEĐUPRODUKTI KORIŠTENI U TOM POSTUPKU
PHARMACEUTICAL COMBINATION COMPRISING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND PARACETAMOL 
FARMACEUTSKE KOMBINACIJE KOJE SADRŽE 3-(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOL I PARACETAMOL
AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE 
GLUKOZA IZOMERAZE ZA UPORABU U LIJEČENJU INTOLERANCIJE FRUKTOZE
Intraocular lens 
INTRAOKULARNA LEĆA
PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS 
FARMACEUTSKA FORMULACIJA NITROOKSIDERIVATA NSAID-a
ADENOVIRUS/ALPHAVIRUS HYBRID VECTOR FOR THE EFFECTIVE ADMINISTRATION AND EXPRESSION OF THERAPEUTIC GENES IN TUMOUR CELLS 
HIBRIDNI VEKTOR ADENOVIRUSA/ALFA VIRUSA ZA EFIKASNU PRIMJENU I EKSPRESIJU TERAPEUTSKIH GENA U STANICAMA TUMORA